• +1-646-491-9876
    • +91-20-67278686

    Search

    Diarrhea - Pipeline Review, H1 2017

    Diarrhea - Pipeline Review, H1 2017

    • Report Code ID: RW0001689411
    • Category Healthcare
    • No. of Pages 163
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea - Pipeline Review, H1 2017, provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape.

    Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Diarrhea - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 15, 2, 21 and 6 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 2 and 4 molecules, respectively.

    Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal).
    - The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Diarrhea (Gastrointestinal) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Diarrhea (Gastrointestinal).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Diarrhea (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 5
    List of Figures 6
    Introduction 7
    Publisher Report Coverage 7
    Diarrhea - Overview 8
    Diarrhea - Therapeutics Development 9
    Pipeline Overview 9
    Pipeline by Companies 10
    Pipeline by Universities/Institutes 14
    Products under Development by Companies 15
    Products under Development by Universities/Institutes 18
    Diarrhea - Therapeutics Assessment 19
    Assessment by Target 19
    Assessment by Mechanism of Action 22
    Assessment by Route of Administration 24
    Assessment by Molecule Type 26
    Diarrhea - Companies Involved in Therapeutics Development 28
    A. Menarini Industrie Farmaceutiche Riunite Srl 28
    Actelion Ltd 28
    Aegis Therapeutics LLC 29
    Akthelia Pharmaceuticals Ltd 29
    Albireo Pharma Inc 30
    AmpliPhi Biosciences Corp 31
    Anatara Lifesciences Limited 32
    Ardelyx Inc 32
    Assembly Biosciences Inc 33
    AzurRx BioPharma Inc 33
    Bharat Biotech International Ltd 34
    CinRx Pharma LLC 34
    Codagenix Inc 35
    Cosmo Pharmaceuticals NV 35
    DesignMedix Inc 36
    DiscoveryBiomed Inc 36
    Genextra Spa 37
    GlaxoSmithKline Plc 37
    GP Pharm SA 38
    Miyarisan Pharmaceutical Company Ltd 38
    Mucosis BV 39
    Napo Pharmaceuticals Inc 39
    Nippon Shinyaku Co Ltd 40
    Novartis AG 40
    Pfizer Inc 41
    Prokarium Ltd 41
    Rebiotix Inc 42
    Recce Ltd 42
    RedHill Biopharma Ltd 43
    RxBio Inc 43
    Scandinavian Biopharma Holding AB 44
    Sigmoid Pharma Ltd 44
    Summit Therapeutics Plc 45
    Synthetic Biologics Inc 45
    Syntiron LLC 46
    Tasly Pharmaceutical Group Co Ltd 46
    Wuhan Institute of Biological Products Co Ltd 47
    Diarrhea - Drug Profiles 48
    ABCD-01 - Drug Profile 48
    ABIM-101 - Drug Profile 50
    AKT-10081 - Drug Profile 51
    ASP-7147 - Drug Profile 52
    AZX-1101 - Drug Profile 53
    Biologic for Irritable Bowel Syndrome with Diarrhea - Drug Profile 54
    cadazolid - Drug Profile 55
    Campylobacter jejuni [strain CPS81-176] vaccine - Drug Profile 57
    CBM-588 - Drug Profile 59
    cholestyramine - Drug Profile 61
    crofelemer DR - Drug Profile 62
    Drugs for Irritable Bowel Syndrome with Diarrhea - Drug Profile 66
    elsiglutide - Drug Profile 67
    Escherichia coli vaccine - Drug Profile 69
    ETEC vaccine - Drug Profile 70
    ETEC vaccine - Drug Profile 71
    Etvax - Drug Profile 72
    GVXNSD-133 - Drug Profile 74
    GXG-8 - Drug Profile 76
    ibodutant - Drug Profile 77
    IMSUTMR-1501 - Drug Profile 78
    infectious diarrhea [serotype H11] vaccine - Drug Profile 79
    LJN-452 - Drug Profile 80
    obeticholic acid - Drug Profile 81
    octreotide acetate - Drug Profile 92
    octreotide acetate MAR - Drug Profile 93
    ondansetron hydrochloride CR - Drug Profile 94
    ORP-101 - Drug Profile 100
    Peptide to Activate NHE-3 for Diarrhea - Drug Profile 101
    PF-06425090 - Drug Profile 102
    prulifloxacin - Drug Profile 104
    PZ-7475 - Drug Profile 106
    RBX-2660 - Drug Profile 107
    RDX-98940 - Drug Profile 110
    RECCE-355 - Drug Profile 111
    Recombinant Enzyme for Diarrhea - Drug Profile 112
    ribaxamase - Drug Profile 113
    ridinilazole - Drug Profile 119
    rifamycin CR - Drug Profile 125
    Rotavac-5C - Drug Profile 128
    rotavirus [serotypes G1, G2, G3, G4, G8, G9] (hexavalent) vaccine - Drug Profile 129
    Rx-100 - Drug Profile 130
    Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis - Drug Profile 132
    Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 133
    Small Molecules for Microbial Infections - Drug Profile 134
    Small Molecules to Inhibit Beta-Glucuronidase for Chemotherapy Induced Diarrhea - Drug Profile 135
    Small Molecules to Inhibit CFTR for Secretory Diarrhea - Drug Profile 136
    SYN-006 - Drug Profile 137
    SYN-007 - Drug Profile 138
    Typhetec - Drug Profile 139
    Vaccine 1 for Diarrhea - Drug Profile 140
    Vaccine 2 for Diarrhea - Drug Profile 141
    Vaccine for Traveler's Diarrhea - Drug Profile 142
    Vaccine for Traveler's Diarrhea - Drug Profile 143
    Yersinia pestis vaccine - Drug Profile 144
    Diarrhea - Dormant Projects 145
    Diarrhea - Discontinued Products 147
    Diarrhea - Product Development Milestones 148
    Featured News & Press Releases 148
    Appendix 158
    Methodology 158
    Coverage 158
    Secondary Research 158
    Primary Research 158
    Expert Panel Validation 158
    Contact Us 158
    Disclaimer 159

    List of Tables

    Number of Products under Development for Diarrhea, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Diarrhea - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2017
    Diarrhea - Pipeline by Actelion Ltd, H1 2017
    Diarrhea - Pipeline by Aegis Therapeutics LLC, H1 2017
    Diarrhea - Pipeline by Akthelia Pharmaceuticals Ltd, H1 2017
    Diarrhea - Pipeline by Albireo Pharma Inc, H1 2017
    Diarrhea - Pipeline by AmpliPhi Biosciences Corp, H1 2017
    Diarrhea - Pipeline by Anatara Lifesciences Limited, H1 2017
    Diarrhea - Pipeline by Ardelyx Inc, H1 2017
    Diarrhea - Pipeline by Assembly Biosciences Inc, H1 2017
    Diarrhea - Pipeline by AzurRx BioPharma Inc, H1 2017
    Diarrhea - Pipeline by Bharat Biotech International Ltd, H1 2017
    Diarrhea - Pipeline by CinRx Pharma LLC, H1 2017
    Diarrhea - Pipeline by Codagenix Inc, H1 2017
    Diarrhea - Pipeline by Cosmo Pharmaceuticals NV, H1 2017
    Diarrhea - Pipeline by DesignMedix Inc, H1 2017
    Diarrhea - Pipeline by DiscoveryBiomed Inc, H1 2017
    Diarrhea - Pipeline by Genextra Spa, H1 2017
    Diarrhea - Pipeline by GlaxoSmithKline Plc, H1 2017
    Diarrhea - Pipeline by GP Pharm SA, H1 2017
    Diarrhea - Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2017
    Diarrhea - Pipeline by Mucosis BV, H1 2017
    Diarrhea - Pipeline by Napo Pharmaceuticals Inc, H1 2017
    Diarrhea - Pipeline by Nippon Shinyaku Co Ltd, H1 2017
    Diarrhea - Pipeline by Novartis AG, H1 2017
    Diarrhea - Pipeline by Pfizer Inc, H1 2017
    Diarrhea - Pipeline by Prokarium Ltd, H1 2017
    Diarrhea - Pipeline by Rebiotix Inc, H1 2017
    Diarrhea - Pipeline by Recce Ltd, H1 2017
    Diarrhea - Pipeline by RedHill Biopharma Ltd, H1 2017
    Diarrhea - Pipeline by RxBio Inc, H1 2017
    Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H1 2017
    Diarrhea - Pipeline by Sigmoid Pharma Ltd, H1 2017
    Diarrhea - Pipeline by Summit Therapeutics Plc, H1 2017
    Diarrhea - Pipeline by Synthetic Biologics Inc, H1 2017
    Diarrhea - Pipeline by Syntiron LLC, H1 2017
    Diarrhea - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
    Diarrhea - Pipeline by Wuhan Institute of Biological Products Co Ltd, H1 2017
    Diarrhea - Dormant Projects, H1 2017
    Diarrhea - Dormant Projects, H1 2017 (Contd..1), H1 2017
    Diarrhea - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Diarrhea, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    A. Menarini Industrie Farmaceutiche Riunite Srl
    Actelion Ltd
    Aegis Therapeutics LLC
    Akthelia Pharmaceuticals Ltd
    Albireo Pharma Inc
    AmpliPhi Biosciences Corp
    Anatara Lifesciences Limited
    Ardelyx Inc
    Assembly Biosciences Inc
    AzurRx BioPharma Inc
    Bharat Biotech International Ltd
    CinRx Pharma LLC
    Codagenix Inc
    Cosmo Pharmaceuticals NV
    DesignMedix Inc
    DiscoveryBiomed Inc
    Genextra Spa
    GlaxoSmithKline Plc
    GP Pharm SA
    Miyarisan Pharmaceutical Company Ltd
    Mucosis BV
    Napo Pharmaceuticals Inc
    Nippon Shinyaku Co Ltd
    Novartis AG
    Pfizer Inc
    Prokarium Ltd
    Rebiotix Inc
    Recce Ltd
    RedHill Biopharma Ltd
    RxBio Inc
    Scandinavian Biopharma Holding AB
    Sigmoid Pharma Ltd
    Summit Therapeutics Plc
    Synthetic Biologics Inc
    Syntiron LLC
    Tasly Pharmaceutical Group Co Ltd
    Wuhan Institute of Biological Products Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//diarrhea-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//diarrhea-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//diarrhea-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments